WebMethods: This is a pre-specified subgroup analysis of the HOST-REDUCE-POLYTECH-ACS trial. ACS patients were randomized to prasugrel de-escalation (5 mg daily) or conventional dose (10 mg daily) at 1-month post-percutaneous coronary intervention. The primary endpoint was a NACE, defined as a composite of all-cause death, non-fatal myocardial ...

Results from host-reduce-polytech-ACS trial reported - Medical Xpress

WebFeb 4, 2024 · Overall, 23,637 patients (62.6%) presented as ACS, and the follow-up duration ranged from 12 to 24 months. Five trials evaluated P2Y12 inhibitor monotherapy compared with DAPT, two trials evaluated the switch from a potent P2Y12 inhibitor to clopidogrel, and one trial evaluated switching the dose of prasugrel from 10 to 5 mg. WebMar 9, 2024 · Design, setting, and participants: This was a post hoc analysis of the HOST-REDUCE-POLYTECH-ACS trial, a randomized, open-label, adjudicator-blinded, multicenter trial performed at 35 hospitals... bottle buzz coupon

De-escalation of antiplatelet therapy after percutaneous coronary ...

WebOct 19, 2024 · Results from host-reduce-polytech-ACS trial reported. A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in ... WebOct 28, 2024 · HOST-REDUCE-POLYTECH-ACS (Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases-Comparison of Reduction of Prasugrel Dose or Polymer Technology in ACS Patients) showed that after 1 month of regular-dose dual antiplatelet therapy (DAPT), reduced-dose prasugrel (5 mg) is superior to regular-dose prasugrel (10 … WebPrasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial hayley goes presenter